Market Cap 17.23M
Revenue (ttm) 41.71M
Net Income (ttm) -10.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -25.27%
Debt to Equity Ratio 0.78
Volume 479,600
Avg Vol 607,582
Day's Range N/A - N/A
Shares Out 14.85M
Stochastic %K 12%
Beta 0.83
Analysts Sell
Price Target $6.00

Company Profile

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 781 245 1325
Address:
660 Main Street, 1st Floor, Woburn, United States
janed102
janed102 Sep. 23 at 2:38 PM
$BFRI stock up by 100% in Europe... 😂 Buying this shit...
0 · Reply
Autolus_Freakk
Autolus_Freakk Sep. 23 at 2:34 PM
$BFRI Why is this not up? https://www.globenewswire.com/news-release/2026/09/14/3361199/0/en/biofrontera-announces-fda-approval-of-ameluz-red-light-pdt-for-the-treatment-of-superficial-basal-cell-carcinoma.html
0 · Reply
ACstranger
ACstranger Sep. 23 at 1:20 PM
$BFRI fockers playing around in premarket. Pathetic!
0 · Reply
DipBuyInvester
DipBuyInvester Sep. 23 at 11:14 AM
0 · Reply
Toptradersam
Toptradersam Sep. 23 at 8:55 AM
$NIO $WAFU $TLSI $BFRG $BFRI I WOULDN’T EXPECT THIS STOCK TO BE ON MY RADAR… 👀🔥 But there’s a reason I’m watching it closely. Check out the full breakdown and join our Discord to follow along with us! 🚀 https://www.youtube.com/watch?v=at1sPc89Rk0
1 · Reply
GJ_Rockabilt
GJ_Rockabilt Sep. 22 at 10:42 PM
$BFRI For modeling Basal Cell Carcinoma related commercial impact on Biofrontera’s Superficial Basal Cell Carcinoma (sBCC))Photodynsmic Therapy (PDT) expansion, the correct CAGR I decide to use is 9–10%. That works for me because: A. It aligns with 2026–2031/2033 windows, B. Matches dermatology device + topical therapy adoption curves, C. It reflects realistic U.S. + EU growth rates.
0 · Reply
ACstranger
ACstranger Sep. 22 at 2:39 PM
$BFRI what am I not seeing. 50m revenue, on the brink of breakeven. 2028 profitable. And a market cap of 15m?
3 · Reply
GJ_Rockabilt
GJ_Rockabilt Sep. 22 at 10:14 AM
$PCSA No thanks, I think I'll stick with my $BFRI recent FDA Approval. I'm not Buying it, on this PCSA uptick, PreMarket. New Officers want new free Shares?
0 · Reply
Timothyb
Timothyb Sep. 21 at 8:33 PM
$BFRI the only fear is cash….nothing else about the company is bad besides the balance sheet and even that is improving…just not there quite yet. Q3 is around the corner and should give us a bounce back if guidance is good and profitability continued in 2026!
2 · Reply
selftaught
selftaught Sep. 21 at 6:52 PM
$BFRI looks like we might be hitting 1.12
1 · Reply
Latest News on BFRI
FDA approves label update for Biofrontera’s Ameluz Gel

2026-09-10T15:55:10.000Z - 12 days ago

FDA approves label update for Biofrontera’s Ameluz Gel


Biofrontera Earnings Call Transcript: Q2 2026

Aug 13, 2026, 10:00 AM EDT - 5 weeks ago

Biofrontera Earnings Call Transcript: Q2 2026


Biofrontera Earnings release: Q2 2026

Aug 13, 2026, 10:00 AM EDT - 5 weeks ago

Biofrontera Earnings release: Q2 2026


Biofrontera Quarterly report: Q2 2026

Aug 13, 2026, 10:00 AM EDT - 5 weeks ago

Biofrontera Quarterly report: Q2 2026


Biofrontera Transcript: AGM 2026

Jun 11, 2026, 10:00 AM EDT - 3 months ago

Biofrontera Transcript: AGM 2026


Biofrontera downgraded to Speculative Buy from Buy at Benchmark

2026-05-19T10:15:31.000Z - 4 months ago

Biofrontera downgraded to Speculative Buy from Buy at Benchmark


Biofrontera Earnings Call Transcript: Q1 2026

May 14, 2026, 11:00 AM EDT - 4 months ago

Biofrontera Earnings Call Transcript: Q1 2026


Biofrontera Earnings release: Q1 2026

May 14, 2026, 11:00 AM EDT - 4 months ago

Biofrontera Earnings release: Q1 2026


Biofrontera Quarterly report: Q1 2026

May 14, 2026, 11:00 AM EDT - 4 months ago

Biofrontera Quarterly report: Q1 2026


Biofrontera Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Biofrontera Proxy statement: Proxy filing


Biofrontera Earnings Call Transcript: Q4 2025

Mar 19, 2026, 10:00 AM EDT - 6 months ago

Biofrontera Earnings Call Transcript: Q4 2025


Biofrontera Annual report: Q4 2025

Mar 19, 2026, 10:00 AM EDT - 6 months ago

Biofrontera Annual report: Q4 2025


Biofrontera Earnings release: Q4 2025

Mar 19, 2026, 10:00 AM EDT - 6 months ago

Biofrontera Earnings release: Q4 2025


Biofrontera reports Q4 revenue $17.1M vs. $12.6M last year

2026-03-19T13:36:56.000Z - 6 months ago

Biofrontera reports Q4 revenue $17.1M vs. $12.6M last year


Biofrontera announces FDA acceptance of sNDA for Ameluz PDT

2026-02-11T14:20:35.000Z - 7 months ago

Biofrontera announces FDA acceptance of sNDA for Ameluz PDT


Biofrontera announces positive Phase 3 results for Ameluz PDT

2026-02-09T14:25:30.000Z - 7 months ago

Biofrontera announces positive Phase 3 results for Ameluz PDT


Biofrontera reports preliminary Q4 revenue $17M-$17.5M

2026-01-13T13:36:29.000Z - 8 months ago

Biofrontera reports preliminary Q4 revenue $17M-$17.5M


Biofrontera announces data base locks for two clinical studies

2026-01-08T14:01:20.000Z - 8 months ago

Biofrontera announces data base locks for two clinical studies


Biofrontera completes transfer of Ameluz, RhodoLED FDA approval

2025-12-18T13:51:20.000Z - 9 months ago

Biofrontera completes transfer of Ameluz, RhodoLED FDA approval


Biofrontera Registration statement: Registration Filing

Dec 5, 2025, 7:00 AM EST - 9 months ago

Biofrontera Registration statement: Registration Filing


Biofrontera files sNDA for Ameluz-PDT in treatment of sBCC

2025-12-02T13:50:16.000Z - 9 months ago

Biofrontera files sNDA for Ameluz-PDT in treatment of sBCC


Biofrontera Earnings Call Transcript: Q3 2025

Nov 13, 2025, 10:00 AM EST - 10 months ago

Biofrontera Earnings Call Transcript: Q3 2025


Biofrontera Earnings release: Q3 2025

Nov 13, 2025, 10:00 AM EST - 10 months ago

Biofrontera Earnings release: Q3 2025


Biofrontera Quarterly report: Q3 2025

Nov 13, 2025, 10:00 AM EST - 10 months ago

Biofrontera Quarterly report: Q3 2025


Biofrontera reports Q3 EPS (62c) vs (98c) last year

2025-11-13T13:21:24.000Z - 10 months ago

Biofrontera reports Q3 EPS (62c) vs (98c) last year


Biofrontera Earnings Call Transcript: Q2 2025

Aug 14, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Earnings Call Transcript: Q2 2025


Biofrontera Earnings release: Q2 2025

Aug 14, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Earnings release: Q2 2025


Biofrontera Quarterly report: Q2 2025

Aug 14, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Quarterly report: Q2 2025


Biofrontera Registration statement: Registration Filing

Aug 13, 2025, 8:00 AM EDT - 1 year ago

Biofrontera Registration statement: Registration Filing


Biofrontera Proxy statement: Proxy Filing

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Biofrontera Proxy statement: Proxy Filing


Biofrontera Proxy statement: Proxy Filing

Jul 25, 2025, 8:00 AM EDT - 1 year ago

Biofrontera Proxy statement: Proxy Filing


Biofrontera Registration statement: Registration Filing

Jul 16, 2025, 8:00 AM EDT - 1 year ago

Biofrontera Registration statement: Registration Filing


Biofrontera Proxy statement: Proxy Filing

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Biofrontera Proxy statement: Proxy Filing


Biofrontera Earnings Call Transcript: Q1 2025

May 16, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Earnings Call Transcript: Q1 2025


Biofrontera Earnings release: Q1 2025

May 16, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Earnings release: Q1 2025


Biofrontera Quarterly report: Q1 2025

May 16, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Quarterly report: Q1 2025


Biofrontera Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Biofrontera Proxy statement: Proxy Filing


Biofrontera Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Biofrontera Proxy statement: Proxy Filing


Biofrontera Earnings Call Transcript: Q4 2024

Mar 21, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Earnings Call Transcript: Q4 2024


Biofrontera Earnings release: Q4 2024

Mar 21, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Earnings release: Q4 2024


Biofrontera Annual report: Q4 2024

Mar 21, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Annual report: Q4 2024


Biofrontera Registration statement: Registration Filing

Jan 17, 2025, 7:00 AM EST - 1 year ago

Biofrontera Registration statement: Registration Filing


Biofrontera Earnings Call Transcript: Q3 2024

Nov 14, 2024, 10:00 AM EST - 1 year ago

Biofrontera Earnings Call Transcript: Q3 2024


Biofrontera Quarterly report: Q3 2024

Nov 14, 2024, 10:00 AM EST - 1 year ago

Biofrontera Quarterly report: Q3 2024


Biofrontera Earnings release: Q3 2024

Nov 14, 2024, 10:00 AM EST - 1 year ago

Biofrontera Earnings release: Q3 2024


Biofrontera Earnings Call Transcript: Q2 2024

Aug 15, 2024, 10:00 AM EDT - 2 years ago

Biofrontera Earnings Call Transcript: Q2 2024


Biofrontera Quarterly report: Q2 2024

Aug 15, 2024, 10:00 AM EDT - 2 years ago

Biofrontera Quarterly report: Q2 2024


Biofrontera Earnings release: Q2 2024

Aug 15, 2024, 10:00 AM EDT - 2 years ago

Biofrontera Earnings release: Q2 2024


janed102
janed102 Sep. 23 at 2:38 PM
$BFRI stock up by 100% in Europe... 😂 Buying this shit...
0 · Reply
Autolus_Freakk
Autolus_Freakk Sep. 23 at 2:34 PM
$BFRI Why is this not up? https://www.globenewswire.com/news-release/2026/09/14/3361199/0/en/biofrontera-announces-fda-approval-of-ameluz-red-light-pdt-for-the-treatment-of-superficial-basal-cell-carcinoma.html
0 · Reply
ACstranger
ACstranger Sep. 23 at 1:20 PM
$BFRI fockers playing around in premarket. Pathetic!
0 · Reply
DipBuyInvester
DipBuyInvester Sep. 23 at 11:14 AM
0 · Reply
Toptradersam
Toptradersam Sep. 23 at 8:55 AM
$NIO $WAFU $TLSI $BFRG $BFRI I WOULDN’T EXPECT THIS STOCK TO BE ON MY RADAR… 👀🔥 But there’s a reason I’m watching it closely. Check out the full breakdown and join our Discord to follow along with us! 🚀 https://www.youtube.com/watch?v=at1sPc89Rk0
1 · Reply
GJ_Rockabilt
GJ_Rockabilt Sep. 22 at 10:42 PM
$BFRI For modeling Basal Cell Carcinoma related commercial impact on Biofrontera’s Superficial Basal Cell Carcinoma (sBCC))Photodynsmic Therapy (PDT) expansion, the correct CAGR I decide to use is 9–10%. That works for me because: A. It aligns with 2026–2031/2033 windows, B. Matches dermatology device + topical therapy adoption curves, C. It reflects realistic U.S. + EU growth rates.
0 · Reply
ACstranger
ACstranger Sep. 22 at 2:39 PM
$BFRI what am I not seeing. 50m revenue, on the brink of breakeven. 2028 profitable. And a market cap of 15m?
3 · Reply
GJ_Rockabilt
GJ_Rockabilt Sep. 22 at 10:14 AM
$PCSA No thanks, I think I'll stick with my $BFRI recent FDA Approval. I'm not Buying it, on this PCSA uptick, PreMarket. New Officers want new free Shares?
0 · Reply
Timothyb
Timothyb Sep. 21 at 8:33 PM
$BFRI the only fear is cash….nothing else about the company is bad besides the balance sheet and even that is improving…just not there quite yet. Q3 is around the corner and should give us a bounce back if guidance is good and profitability continued in 2026!
2 · Reply
selftaught
selftaught Sep. 21 at 6:52 PM
$BFRI looks like we might be hitting 1.12
1 · Reply
selftaught
selftaught Sep. 21 at 6:40 PM
$BFRI tasty dip
1 · Reply
ACstranger
ACstranger Sep. 21 at 6:25 PM
$BFRI Q: Can you provide more details on the sales force expansion and the expected return on investment for these new hires? A: The Chief Commercial Officer noted that we increased our field sales team by 20% in the first half of 2026, targeting high-prescribing dermatologists. The productivity of new reps is ramping up faster than historical averages, and we expect the full contribution of this expanded team to be realized in the fourth quarter, driving incremental revenue growth.
1 · Reply
User123321
User123321 Sep. 21 at 5:56 PM
$BFRI 50% year range fib is at $1.1075 and the 61.8% is at $.9771. Good luck.
0 · Reply
ACstranger
ACstranger Sep. 21 at 5:53 PM
$BFRI buying another lot..
0 · Reply
Trending__Now
Trending__Now Sep. 21 at 5:28 PM
$BFRI $THUNDERCOOPERSMITH My thoughts for what they're worth. A main reason would be lack of major institutional ownership around 20%. That's great for you and I because they'll be buying our shares at a higher price when revenues come to fruition. I typically don't invest in medical equipment suppliers because their upside is limited. However, the current price is depressed for the potential. Low risk. Renaissance has begun to acquire shares. That's worth noting and I trust at some point they'll show they've acquired more. I like to watch them for that warm fuzzy feeling that maybe, just maybe they see the same value considering their history. Good luck.
1 · Reply
Trending__Now
Trending__Now Sep. 21 at 5:07 PM
$BFRI Adding a tranche on this dip. Buying the down days, but that's me.
0 · Reply
ThunderCoopersmith
ThunderCoopersmith Sep. 21 at 5:00 PM
$BFRI down 25% since a cancer treatment approval? lol can’t make this shit up.
1 · Reply
polishsmokestack
polishsmokestack Sep. 21 at 4:55 PM
$BFRI Today and then only 4...FOUR...trading days left and this is down..??????
1 · Reply
User123321
User123321 Sep. 21 at 4:50 PM
$BFRI I thought I posted this a short time ago but low to high in the one year is $.555-1.66 so a 200% range low to high. If 1.17 doesn’t hold there’s a lot going on in the $1.10-$1.11 area. It’s the overall low to high 50% fib at $1.1075 and the 200 EMA is at $1.11 with the 50 week EMA at $1.10. It’s just a level but one to watch. Good luck.
0 · Reply
ACstranger
ACstranger Sep. 21 at 3:52 PM
$BFRI 10% down...no reason whatever!
1 · Reply
ACstranger
ACstranger Sep. 21 at 3:48 PM
$BFRI this is pure manipulation...probably that youvsyou character...sell and be sorry...
0 · Reply
DueDilly102
DueDilly102 Sep. 21 at 3:35 PM
$BFRI kinda crazy how they have good growth and another approval and we're down. Should be going deep on this one as a de risked investment.
1 · Reply